Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(31 sites)

China

Novartis Investigative Site, Nanjing, Jiangsu

Novartis Investigative Site, Beijing

Novartis Investigative Site, Shanghai

France

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Paris

Novartis Investigative Site, Rouen

Novartis Investigative Site, Toulouse

Novartis Investigative Site, Tours

Germany

Novartis Investigative Site, Essen

Novartis Investigative Site, Kiel

Italy

Novartis Investigative Site, Ranica, BG

Novartis Investigative Site, Milan, MI

Novartis Investigative Site, Roma, RM

Japan

Novartis Investigative Site, Matsumoto-shi, Nagano

Novartis Investigative Site, Iruma-gun, Saitama

Novartis Investigative Site, Bunkyo Ku, Tokyo

Spain

Novartis Investigative Site, Santiago Compostela, A Coruna

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Córdoba

Novartis Investigative Site, Málaga

Novartis Investigative Site, Seville

Novartis Investigative Site, Valencia

Turkey (Türkiye)

Novartis Investigative Site, Izmir, Balcova

Novartis Investigative Site, Köseköy, Kocaeli

Novartis Investigative Site, Ankara, Yenimahalle

Novartis Investigative Site, Mersin, Yenisehir

United Kingdom

Novartis Investigative Site, Glasgow, Scotland

Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear

Novartis Investigative Site, London